DEA
DEA and Morris & Dickson Announce Settlement
The Drug Enforcement Administration (DEA) recently announced a settlement with pharmaceutical distributor Morris & Dickson Co., LLC (Morris & Dickson) for failing to maintain effective controls against diversion of controlled substance, which included the failure to report thousands of unusually large orders of oxycodone and hydrocodone. As part of the settlement last month, Morris &…
Read MoreDEA Sues the Colorado Board of Pharmacy over PDMP Data
Last week, the Drug Enforcement Administration (DEA) sued the Colorado Board of Pharmacy (Board) demanding that the Board share its Prescription Drug Monitoring Program (PDMP) data to assist in an ongoing investigation as to whether two unnamed pharmacies broke the law in dispensing opioids and other drugs. Colorado’s PDMP program tracks opioid and other prescription…
Read MoreNABP Statement on Prescription Drug Importation Proposals
Last month the National Association of Boards of Pharmacy (NABP) released a ‘Statement on Prescription Drug Importation Proposals‘ reiterating its stance that prescription drug importation is not a viable solution to addressing high prescription drug costs. The NABP statement is in response to recent policymaker proposals seeking to allow (1) the importation of prescription drugs…
Read MoreEpidiolex (Cannabidiol) is a Schedule V Controlled Substance
Yesterday, the Drug Enforcement Administration announced that Epidiolex, which contains cannabidiol (CBD), a chemical constituent of the cannabis or marijuana plant is a Schedule V Controlled Substance, which is the least restrictive schedule of the Controlled Substance Act. In June 2018, the Food and Drug Administration announced it approved Epidiolex (cannabidiol), for the treatment of…
Read MoreAG Sessions Announces DEA Surge to Combat Prescription Drug Diversion
Attorney General Jeff Sessions announced this week that the Drug Enforcement Administration (DEA) will surge Special Agents, Diversion Investigators and Intelligence Research Specialists over the next 45 days to focus on pharmacies and prescribers who are dispensing unusual or disproportionate amounts of controlled substances. The DEA plans to analyze the data from 80 million transaction…
Read More